Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant lapatinib + oxaliplatin + capecitabine in HER2-positive gastric or gastroesophageal adenocarcinoma
2010-021118-47Phase 2Terminated
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Jul 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib, oxaliplatin and capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Fundación de Investigación HM Hospitales. Primary endpoint: Pathologic complete response rate. Started Jul 2010; status: terminated.
02
Drugs
lapatiniboxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2010-021118-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021118-47.